Tradestie Institutional Equity Comparison Engine
IMDX vs LCTX โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
LCTX Overall Edge
LCTX Captures Institutional Edge (4โ0 Pillars ยท 8โ2 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Lineage Cell Therapeutics, Inc. (LCTX) driven by superior Valuation, Growth & Margin, Momentum & Technical, Options & Structure. Fundamentally, IMDX trades at N/M Forward P/E with -1883.2% operating margin (+115.0% YoY revenue) versus LCTX at 30.7x Forward P/E and -280.3% operating margin (-61.0% YoY). In options structure, IMDX sits in BREAKDOWN (12th %ile IV; Dealer Gamma Walls on Pro) against LCTX sits in BREAKDOWN (100th %ile IV; Dealer Gamma Walls on Pro).
Valuation Winner
LCTX
IMDX N/M vs LCTX 30.7x Fwd P/E
Growth & Margin Winner
LCTX
Op Margin -1883.2% vs -280.3% ยท YoY +115.0% vs -61.0%
Momentum & Technical Winner
LCTX
1Y -73.8% vs -53.7% ยท 52W Pos 3% vs 4%
Options & Structure Winner
LCTX
BREAKDOWN (12th %ile IV) vs BREAKDOWN (100th %ile IV)
IMDX
NASDAQ
Insight Molecular Diagnostics Inc. Common Stock
In Vitro & In Vivo Diagnostic Substances
$1.66
+4.4% 1D
Market Cap
$52.1M
1M Return
-45.03%
1Y Return
-73.78%
Forward P/E
N/M
Unified AI Score
45.5 / 100
HOLD
Tech 50.0
Fund 40.0
Flow 58.0
Mom 40.0
LCTX
NYSE American
Lineage Cell Therapeutics, Inc.
Biological Products, (No Disgnostic Substances)
$0.82
-2.21% 1D
Market Cap
$212.1M
1M Return
-13.82%
1Y Return
-53.67%
Forward P/E
30.7x
Unified AI Score
58.9 / 100
HOLD
Tech 65.0
Fund 54.0
Flow 65.0
Mom 45.0
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
1Y Indexed Return:
IMDX -73.78%
LCTX -53.67%
Spread: +20.11 pp (LCTX Lead)
Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | IMDX Revenue | LCTX Revenue | IMDX Op. Margin | LCTX Op. Margin | Margin Edge |
|---|---|---|---|---|---|
| FY2018 | N/A | $0M | N/A | -837.9% | LCTX |
| FY2019 | N/A | $0M | N/A | -1106.0% | LCTX |
| FY2020 | $0M | $0M | -2443.3% | -1448.4% | LCTX |
| FY2021 | $0M | $0M | -2444.3% | -1133.6% | LCTX |
| FY2022 | $0M | $10M | -1878.6% | -153.2% | LCTX |
| FY2023 | $0M | $10M | -1672.4% | -276.5% | LCTX |
| FY2024 | $0M | $10M | -3245.1% | -226.1% | LCTX |
| FY2025 | $0M | $10M | -1260.8% | -251.6% | LCTX |
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | IMDX | LCTX | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $52.1M | $212.1M | Larger Scale | LCTX |
| Trailing P/E Ratio Valuation | N/M | 30.7x | Lower Multiple | LCTX |
| Forward P/E Ratio Valuation | N/M | 30.7x | Lower Multiple | LCTX |
| Revenue Growth (YoY) Growth | +115.0% | -61.0% | Higher Growth | IMDX |
| Operating Margin (TTM) Profitability | -1883.2% | -280.3% | Higher Margin | LCTX |
| Net Profit Margin Profitability | 0.0% | 16.2% | Higher Margin | LCTX |
| Return on Equity (ROE) Capital Efficiency | -23603.1% | 4.3% | Higher ROE | LCTX |
| 52-Week Range Position Momentum | 3% ($2โ$8) | 4% ($1โ$2) | Stronger Trend | LCTX |
| Beta / 30D Volatility Risk Regime | 2.91ฮฒ ยท 76% Vol | 1.36ฮฒ ยท 79% Vol | Lower Realized Risk | IMDX |
| Unified Institutional Score Composite Signal | 45.5 / 100 (HOLD) | 58.9 / 100 (HOLD) | Higher Composite | LCTX |
Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor
Full IMDX vs LCTX Buy Guide
IMDX
BREAKDOWN
117d in phase ยท OBV DISTRIBUTION
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
12th %ile
IV Regime
Compressed (<25th %ile)
LCTX
BREAKDOWN
6d in phase ยท OBV DISTRIBUTION
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
100th %ile
IV Regime
Extreme (>80th %ile)
Pillar 6 90-Day Technical & R&D Innovation Disclosures
Corporate R&D & Foundry Tracker
Neither IMDX nor LCTX registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.